Try to Continue the New Cystic Fibrosis Meds During a Hospital Stay

Tezacaftor/ivacaftor (Symdeko, SIM-deh-koh) will raise questions about handling new cystic fibrosis (CF) meds during a hospital stay.

Symdeko joins other CF transmembrane conductance regulator (CFTR) modulators...lumacaftor/ivacaftor (Orkambi) and ivacaftor (Kalydeco).

Expect to see more patients on these game-changing meds...since they'll be first-line agents for patients who qualify.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals